belzutifan + palbociclib

Belzutifan + palbociclib is an investigational combination therapy composed of **belzutifan**, a selective small molecule inhibitor of hypoxia-inducible factor 2-alpha (HIF-2α), and **palbociclib**, a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. This dual-targeted regimen aims to treat advanced clear cell renal cell carcinoma (ccRCC) by inhibiting complementary oncogenic pathways: belzutifan blocks HIF-2α downstream signaling crucial for tumor growth in VHL-deficient tumors, while palbociclib suppresses cell cycle progression by inhibiting the CDK4/6-cyclin D pathway. Preclinical data show synergistic anti-tumor effects, and the combination is being investigated in the LITESPARK-024 randomized phase 1/2 clinical trial for patients with progressive, metastatic ccRCC who have failed multiple prior therapies[1][5][6].